- Open Access
Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells
© Banerjee et al; licensee BioMed Central Ltd. 2009
- Received: 12 March 2009
- Accepted: 27 April 2009
- Published: 27 April 2009
Probiotic microorganisms are receiving increasing interest for use in the prevention, treatment, or dietary management of certain diseases, including antibiotic-associated diarrhea (AAD). Clostridium difficile is the most common cause of AAD and the resulting C. difficile – mediated infection (CDI), is potentially deadly. C. difficile associated diarrhea (CDAD) is manifested by severe inflammation and colitis, mostly due to the release of two exotoxins by C. difficile causing destruction of epithelial cells in the intestine. The aim of this study was to determine the effect of probiotic bacteria Lactobacillus delbrueckii ssp. bulgaricus B-30892 (LDB B-30892) on C. difficile-mediated cytotoxicity using Caco-2 cells as a model.
Experiments were carried out to test if the cytotoxicity induced by C. difficile- conditioned-medium on Caco-2 cells can be altered by cell-free supernatant (CFS) from LDB B-30892 in different dilutions (1:2 to 1:2048). In a similar experimental setup, comparative evaluations of other probiotic strains were made by contrasting the results from these strains with the results from LDB B-30892, specifically the ability to affect C. difficile induced cytotoxicity on Caco-2 monolayers. Adhesion assays followed by quantitative analysis by Giemsa staining were conducted to test if the CFSs from LDB B-30892 and other probiotic test strains have the capability to alter the adhesion of C. difficile to the Caco-2 monolayer. Experiments were also performed to evaluate if LDB B-30892 or its released components have any bactericidal effect on C. difficile.
Results and discussion
Co-culturing of LDB B-30892 with C. difficile inhibited the C. difficile- mediated cytotoxicity on Caco-2 cells. When CFS from LDB B-30892-C. difficile co-culture was administered (up to a dilution of 1:16) on Caco-2 monolayer, there were no signs of cytotoxicity. When CFS from separately grown LDB B-30892 was mixed with the cell-free toxin preparation (CFT) of separately cultured C. difficile, the LDB B-30892 CFS was inhibitory to C. difficile CFT-mediated cytotoxicity at a ratio of 1:8 (LDB B-30892 CFS:C. difficile CFT). We failed to find any similar inhibition of C. difficile- mediated cytotoxicity when other probiotic organisms were tested in parallel to LDB B-30892. Our data of cytotoxicity experiments suggest that LDB B-30892 releases one or more bioactive component(s) into the CFS, which neutralizes the cytotoxicity induced by C. difficile, probably by inactivating its toxin(s). Our data also indicate that CFS from LDB B-30892 reduced the adhesion of C. difficile by 81%, which is significantly (P <0.01) higher than all other probiotic organisms tested in this study.
This study reveals the very first findings that Lactobacillus delbrueckii ssp. bulgaricus B-30892 (LDB B-30892) can eliminate C. difficile-mediated cytotoxicity, using Caco-2 cells as a model. The study also demonstrates that LDB B-30892 can reduce the colonization of C. difficile cells in colorectal cells. More study is warranted to elucidate the specific mechanism of action of such reduction of cytotoxicity and colonization.
- Clostridium Difficile
- Cell Free Supernatant
- Lactobacillus Acidophilus
- Bifidobacterium Longum
Use of probiotic organisms to reduce and alleviate antibiotic-associated diarrhea (AAD) is receiving increasing interest in recent years [1–3]. Clostridium difficile is responsible for a potentially deadly bacterial infection and it is the most common etiologic agent of AAD or more precisely, a C. difficile associated diarrhea or colitis (CDAD or CDAC), resulting in severe diarrhea and inflammation [4, 5]. The principal pathogenic determinants of C. difficile are two large exotoxins; A (TcdA) and B (TcdB), which are implicated for the clinical symptoms . Traditionally, TcdA was considered to be the major component in eliciting the disease. More recently an equally important role of TcdB in pathogenesis has been demonstrated . Cell death or cytotoxicity induced by Tcds is initiated by the glycosylation, followed by inactivation, of the small GTPases, Rho, Rac and Cdc-42 causing perturbations in the arrangement of actin cytoskeleton leading to cell death via apoptosis [7, 8]. Along with Rho-GTPase dependent apoptosis event, Tcds are also reported to elicit apoptotic cell death via caspase-dependent pathways [7, 9, 10]. Disruption of the functionality of human and animal epithelial cell barriers by Tcds is believed to be caused by the above-mentioned mechanisms, where the toxins cause dysfunction of tight junctions in intestinal epithelia due to disaggregation of filamentous actin, resulting in cell detachment and rounding [8, 11]. Inflammatory events in the intestine are also implicated as hallmarks of C. difficile infection (CDI) along with cytotoxicity, apoptotic and necrotic cell death . Production of cytokines (interleukins 1–8, leukotrienes, histamine, etc.) and other inflammatory mediators from cells of the intestinal epithelial layer and lamina propria is triggered when TcdA or TcdB or both bind to receptors on intestinal epithelial cells [5, 12–14]. The Tcds binding event results in the infiltration and activation of polymorphonuclear neutrophils (PMNs) [14, 15]. Severe damage is done to villous enterocytes by PMN-derived inflammatory mediators, which act on these epithelial cells causing acute destruction and necrosis [14, 15].
The incidence of CDI is increasing rapidly and is further complicated by the emergence of a more virulent, drug-resistant strain . It is estimated that there are between 250,000 – 500,000 cases of CDI in the U.S. each year, resulting in longer hospital stays and an estimated $1.1 billion in additional costs [16, 17]. Current treatment of CDAD, a regimen that has existed for the last 25 years, includes metronidazole or oral vancomycin along with discontinuation of the offending agent. Impaired colonization resistance frequently occurs following antibiotic therapy in hospitalized patients . Emergence of new multi-drug resistant epidemic strains poses a great challenge to the effective treatment of CDI . Along with conventional antibiotic therapy, administration of probiotic organisms to manage CDAD is drawing increasing attention . Use of probiotic organisms such as Saccharomyces boulardii [20, 21]; Lactobacillus plantarum 299v [22, 23]; Lactobacillus rhamnosus GG [24, 25]; Lactobacillus acidophilus and Bifidobacterium bifidum  in conjunction with metronidazole or oral vancomycin therapy are reported in cases of CDAD [19–21]. Similarly, several reports of use of other probiotic organisms, individually and in combination with other strains, can be found in scientific reports in adult and infant AAD cases. These probiotic therapies include the use of Lactobacillus rhamnosus GG; Bacillus clausii; Bifidobacterium longum; Clostridium butyricum MIYAIRI; Enterococcus faecium SF68; Lactobacillus acidophilus; L. acidophilus and L. bulgaricus (Lactinex); Lactobacillus acidophilus and Bifidobacterium longum; Lactobacillus acidophilus and Bifidobacterium lactis; Bifidobacterium lactis and Streptococcus thermophilus; Lactobacillus sporogenes and fructo-oligosaccharide; Lactobacillus acidophilus and Bifidobacterium infantis [reviewed and analyzed in detail by McFarland, 2006 ]. The totality of evidence in these reports emphasizes the increased attention to probiotics and supports their inclusion as a choice of therapy, along with or in parallel with conventional antibiotic regimens, to prevent AAD or CDAD.
In the present study, we evaluated the efficacy of Lactobacillus delbrueckii ssp. bulgaricus B-30892, a probiotic bacteria found to be effective in inflammatory bowel disease as well as diarrhea, AAD, and CDAD [28, 29], on C. difficile- mediated cytotoxicity on human enterocyte-like Caco-2 cell model.
Bacterial Strains and Culture Conditions
List of different lactobacilli and C. difficile strains or isolates used
Designation or Code
L. delbrueckii ssp. bulgaricus B-30892
L. delbrueckii ssp. bulgaricus
From commercial probiotic supplement
From commercial probiotic supplement
From Dr. A Bhunia, Purdue University
From commercial probiotic dairy drink
From Dr. A Bhunia, Purdue University
L. delbrueckii ssp. bulgaricus
From commercial yogurt
Clostridium difficile strain 9689
Human Intestinal Cell Culture
The human intestinal epithelial cell line, Caco-2 (HTB-37), was purchased from the ATTC and cultured in Dulbecco's Modified Eagle medium (DMEM; Gibco, Invitrogen Corp.) with 20% fetal bovine serum (FBS). This cell line has been well established as a model to study the intestinal barrier function . For the cytotoxicity assays, Caco-2 cells were grown to confluency in 96-well cell culture plates (Falcon, BD) at 37°C in 7% CO2.
The effect of different lactobacilli on C. difficile induced cytotoxicity on a Caco-2 cell monolayer was tested using two groups of bacterial cell free supernatant (CFS) or bacterial conditioned medium (cell free) as described below:
CFS from co-culture
The bacterial strains were grown in 10 ml of the appropriate broth, anaerobically, at 37°C for 72 h. Twenty-four hours before the cytotoxicity experiment, one LDB B-30892 culture was centrifuged and the resulting pellet was resuspended into one C. difficile culture. Such lactobacilli cultures when added to C. difficile culture and grown together are designated as 'co-culture' in the present article. All bacterial cultures, controls and the mixed LDB B-30892/CD-9689 culture (LDB-CD co-culture), and mixture of other lactobacilli/C. difficile cultures (LB-1/CD-9689 through LB-6/CD-9689, Table 1, LB-CD co-culture) were then incubated anaerobically at 37°C for an additional 24 h. In some experiments, LDB B-30892 was heat-killed at 70°C for 45 min before centrifuging and resuspending in a CD-9689 culture. The CD-9689, LDB B-30892, and mixed lactobacilli/C. difficile cultures described above were centrifuged (10,000 g, 10 min, 5°C) and the supernatants collected and filter-sterilized (0.45 μm pore size). Thus several cell free supernatants were obtained from lactobacillus-clostridium co-cultures. The cytotoxicity of these filter-sterilized media, cell-free toxin preparation (CFT), and CFS containing lactobacilli 'factors' were tested on Caco-2 cultures as described below.
CFS mixture from individually grown cultures
In this case, we grew the lactobacilli (LDB and other LB-1 through LB-6) and C. difficile CD-9689 cultures individually under the conditions described above. All the different cultures (lactobacilli and Clostridium) were centrifuged (10,000 g, 10 min, 5°C) and the supernatants collected and filter-sterilized (0.45 μm pore size). Thus we obtained individual CFSs from all the eight bacterial cultures (Table 1). After this, CFS from LDB B-30892 (LDB-CFS) culture was added in different ratio to the crude toxin preparation from CD-9689 (CD-CFT) culture resulting in a cocktail of LDB-CFS + CD-CFT and tested for Caco-2 cytotoxicity. Similarly, the CFS obtained from six other commercially available probiotic and conventional lactobacilli strains, LB-1 through LB-6, designated as LB-CFS were mixed individually with CD-CFT and tested for cytotoxicity.
On the day of the cytotoxicity assay, the cell culture medium was removed from the Caco-2 monolayers and replaced with fresh cell culture media or various dilutions (1:2 through 1:2048 into DMEM, 20% FBS) of sterile RCM, sterile MRS, or the cell free supernatants (CFS or CFT) samples from various organisms (prepared as described above, either by co-culturing or obtained from separately grown cultures). The Caco-2 cultures were then incubated for 24 h. Cytotoxicity effects were assessed microscopically by examining the Caco-2 cell monolayers in multiwall plates with an inverted microscope as described below.
Photomicroscopic Analysis of Cytotoxic Effects
For photomicroscopy, similar cytotoxicity experiments as described above were conducted, except the Caco-2 cells were grown to confluency in Lab-Tek II Chamber Slide Systems (Nalge Nunc International Corp., Naperville, IL). Following treatment with toxin or antitoxin preparations for 24 h, the monolayers were washed once with PBS (20 mM, pH 7.2), fixed with 10% formalin in PBS for 10 min, the media chambers removed, and the slides were mounted with coverslips and Gel/Mount mounting medium (Biomeda Corp., Foster City, CA). Microscopic images were captured using a Leica DMRXA2 phase contrast microscope equipped with a Spot RTKE digital camera and software.
Live-Dead Analysis using Fluorescence Microscopy
We deduced the efficacy of LDB B-30892 in protecting Caco-2 cells from cytotoxic effect of CD-CFT, and compared that with other lactobacilli by a live-dead assay using two fluorescence dyes, propidium iodide (PI, red, dead cell indicator) and acridine orange (AO, green, live cell indicator), as described previously .
Briefly, a cell staining solution containing 20 μg/ml of AO and 100 μg/ml PI (Sigma) was prepared in sterile de-ionized water. The Caco-2 cells (exposed to toxins or anti-toxin preparations, as described in previous sections) were dislodged by trypsin treatment. Aliquots of 100 μl of cell suspension (1 – 2 × 106/ml) were mixed with 100 μl of staining solution and analyzed immediately with a fluorescence microscope (Leica, model DMLB, Wetzlar, Germany, with SPOT software, version 188.8.131.52, Diagnostic Instruments, Sterling Heights, MI, USA), using green (for AO) and red filters (for PI). The detection of live (L), and dead (D) cells were done in the following manner, green (live), red (necrotic), both by visual scoring on a hemacytometer and by using image analysis software, SPOT, version 184.108.40.206 (image acquisition) and ImageJ v1.38 (NIH, USA) with "color counter" (v2001) and "color histogram" plug-ins (v2007) to analyze the images.
The goal of the adhesion assay was to investigate the ability of the cell free conditioned medium (CFSs) obtained from LDB B-30892 and other lactobacilli to modulate the adhesion of CD-9689 to the intestinal epithelial cell monolayer in vitro. The experimental set-up for this was similar to the detoxification experiment using Caco-2 cell as model. The adhesion assay was done as described previously [32–34] with some modification. In short, Caco-2 cells (1.1 × 104 cells/ml) at the post-confluence stage were seeded on Lab-Tek II Chamber Slide Systems (Nalge Nunc International, USA). After incubation for 14 days at 37°C in 7% CO2, the slides were washed with sterile PBS buffer and the test bacterial suspension of CD-9689 (with multiplicity of infection of 100 C. difficile cells to one Caco-2 cell; the C. difficile suspension medium in this case was a 1:1 volume/volume RCM-lactobacilli CFS) was added to each chamber with a Caco-2 monolayer. A 1:1 volume/volume RCM-MRS (without any lactobacillus conditioning) served as the control. The chambered slides were incubated at 37°C in 7% CO2 for 2 h. After incubation, Caco-2 cells were washed four times with PBS and then immersed in PBS for 30 s. Cells were immersed in 1.0 ml of 100% ethanol for 5 min, air dried, and immersed in 1.0 ml of Giemsa staining solution (2.5 ml of KaryoMAX Giemsa staining solution [Invitrogen Corp., Carlsbad, Calif.] and 48.5 ml of 10 mM potassium phosphate buffer [20 mM KH2PO4, 20 mM K2HPO4; pH 6.8]), washed twice with distilled water, air dried again, and examined under a Leica DAS Mikroskop at a magnification of ×1,000. Counts of bacterial adhesion were taken at four to five random locations for a total of at least 150 Caco-2 cells, averaged, and statistically analyzed by the Duncan test by using SAS software (SAS Institute, Cary, N.C.). The inhibition of adhesion was calculated by taking the adhesion of CD-9689 without any treatment as 100 percent by the formula described.
Growth inhibition assay
Co-cultures of C. difficile (CD-9689) and Lactobacillus (LDB B-30892) on solid medium as well as in broth were done. In one such study, CD-9689 was streaked on RCM agar and cross-streaked with LDB B-30892. In some other experiments, CD-9689 and LDB B-30892 were co-cultured in RCM broth followed by selective plating on RCM and MRS agar plates, respectively. To study if the LDB-CFS caused any growth inhibition on CD-9689 cells, different ratios of LDB-CFS were added to RCM containing CD-9689 cells. All plates and tubes were incubated anaerobically at 37°C.
Data are expressed as mean ± Standard Error of Mean (SEM). Statistical analyses of data were performed using GraphPad Prism (version 3.02, GraphPad Software, San Diego, CA). Comparisons of cytotoxicity values between single control and CFS or CFT exposed sample means were made using two-tailed Student's t test or Tukey's pairwise comparison test. The limit for statistical significance was set at P < 0.05. Results of inhibition of adhesion assay were statistically analyzed by the Duncan test by using SAS software (SAS Institute, Cary, N.C.).
Diminished cytotoxic effect of Clostridium difficile (CD-9689) in presence of Lactobacillus delbruckeii ssp. bulgaricus B-30892 on Caco-2 cells
The lack of a cytotoxic effect shown in Figure 1E provided clues that CFT from CD-9689-conditioned RCM was no longer cytotoxic after co-culturing with LDB B-30892, possibly due to detoxification of the C. difficile cytotoxin(s) by LDB B-30892 or factor(s) produced by this organism. To verify this effect, we preformed a semi-quantitative assessment of C. difficile cytotoxin activity and its detoxification by LDB B-30892.
Effect of sterile media and CFS/CFT from CD-9689 and LDB B-30892 co-culture on Caco-2 cells.
Media only or CFS
Appearance of Caco-2 cells
CD-9689 CFS (CFT)
LDB B-30892 CFS (LDB-CFS)
LDB B-30892 – CD-9689 co-culture CFS
Heat-killed LDB B-30892 – CD-9689 co-culture CFS
Based on these initial in-vitro observations, we further investigated the following two issues: (i) Does LDB B-30892 release a bioactive component in the CFS, which results in the detoxification of C. difficile- mediated cytotoxicity; and (ii) Is the detoxification of C. difficile- mediated cytotoxicity unique to LDB B-30892?
To test the first question, LDB B-30892 and CD-9689 were grown separately in MRS and RCM broth, respectively, under the conditions mentioned earlier. CFS from the LDB B-30892 culture was added in different ratios to CFT from the CD-9689 culture (in a similar manner as in the semi-quantitative assay described above). We found that CFS from LDB B-30892 culture inhibited the cytotoxic effects of CFT from CD-9689 culture when added at a ratio of 1:1 through 1:8, and this inhibitory effect diminished in ratios lower than 1:16. These results indicate that LDB B-30892-conditioned CFS contains a bioactive component(s) or in other words, LDB B-30892 releases one or more extracellular components in the growth medium, which were responsible for inhibiting or deactivating the exotoxins released by C. difficile (in growth medium), thus protecting Caco-2 cells from C. difficile- mediated cytotoxicity.
Figure 2A depicts control Caco-2 cells without any treatment; most cells are viable as they incorporated AO but not PI. Caco-2 cells treated with CFT from CD-9689 are shown in Figure 2B, where most of the cells were dead as indicated by the incorporation of PI by the vast majority of the cells. Figures 2C and 2D represent the protective effect of LDB B-30892-conditioned CFS on Caco-2 cells when co-cultured (Fig 2C) with CD-9689 or when separately cultured LDB-CFS was added to CFT from CD-9689 (Fig 2D). In both Figures 2C and 2D, the vast majority of the cells excluded PI (red fluorescence) indicating a higher live cell population. However, no other lactobacilli tested in the present study were able to detoxify CD-9689-conditioned CFT as similarly demonstrated by LDB B-30892 CFS. Figures 2E and 2F show the inability of LB-4, a L. casei isolated from a commercial probiotic yogurt and LB-1, a L. delbrueckii ssp. bulgaricus isolated from a probiotic supplement, to inhibit the cytotoxicity induced by CFT from CD-9689, as depicted by higher PI counts indicating that the majority of cells are dead.
Figure 3 shows the counts of live and dead Caco-2 cells after exposure to CFT from CD-9689, with or without treatments with different lactobacilli CFS. A mixture of cell-free extracts from CD-9689/LDB B-30892 at a ratio of 1:1 resulted in less than 4% cell death, while the mixture at a ratio of 4:1 caused only 12% cell death. No other probiotic organisms tested could result in such protection of Caco-2 cell death when the probiotic CFS aliquots were mixed to CD-9689-CFT.
The lack of a cytotoxic effect of CD-9689 in the presence of LDB B-30892-conditioned CFS on Caco-2 cells is thought to be due to a possible proteolytic activity of the antitoxic component released by LDB B-30892. Indeed, a similar detoxification of the C. difficile toxin A and B by a protease produced by Saccharomyces boulardii has been reported [35, 36].
Lactobacillus delbruckeii ssp. bulgaricus B-30892 can inhibit the adhesion of Clostridium difficile to human colonic cells
Lactobacillus delbruckeii ssp. bulgaricus B-30892 did not inhibit the growth of Clostridium difficile
In the present study, we have gathered initial evidences which indicated that cell-free supernatant (alternatively, the conditioned medium) from probiotic L. bulgaricus LDB B-30892 reduced the cytotoxicity produced by pathogenic C. difficile ATCC 9689. At the same time, the adhesion of C. difficile was reduced significantly (P < 0.01) by LDB B-30892. We hypothesize that one or more bioactive component(s) is released by LDB B-30892 in its growth medium (CFS), which is (or are) the probable causative agent(s) of inhibition of cytotoxins, i.e., detoxification and inhibition of adhesion which may occur via several possible mechanisms, such as, proteolytic cleavage of toxin or toxin receptors, blockage of toxin receptors or C. difficile adhesion molecules on host cells by competitive binding by the bioactive agent(s). However, the specific mechanism of the detoxification and diminished adhesion of C. difficile in presence of CFS from LDB B-30892 remains to be elucidated. In future, we plan to purify the bioactive component(s) from LDB B-30892-CFS, further characterize and investigate the underlying mechanism of reduced cytotoxicity and adherence of C. difficile on Caco-2 cells.
The authors acknowledge Barbara Scofield of IU School of Medicine and Briana Franz of Molecular Food Microbiology laboratory at Purdue University's Food Science department for their technical assistance and to Melinda Schriver for her critical reading and comments on the manuscript.
- Marshall JC: Daily use of a Lactobacilli probiotic prevented antibiotic-associated diarrhea in hospitalized patients. ACP J Club. 2008, 149 (1): 10-PubMedGoogle Scholar
- Doron SI, Hibberd PL, Gorbach SL: Probiotics for prevention of antibiotic-associated diarrhea. J Clin Gastroenterol. 2008, 42 (Suppl 2): S58-63. 10.1097/MCG.0b013e3181618ab7.View ArticlePubMedGoogle Scholar
- Hickson M, D'Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C, Bulpitt CJ: Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ. 2007, 335 (7610): 80-10.1136/bmj.39231.599815.55.PubMed CentralView ArticlePubMedGoogle Scholar
- Calfee DP: Clostridium difficile: a reemerging pathogen. Geriatrics. 2008, 63 (9): 10-21.PubMedGoogle Scholar
- Kelly CP, LaMont JT: Clostridium difficile – more difficult than ever. N Engl J Med. 2008, 359 (18): 1932-1940. 10.1056/NEJMra0707500.View ArticlePubMedGoogle Scholar
- Voth DE, Ballard JD: Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005, 18 (2): 247-263. 10.1128/CMR.18.2.247-263.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Bobak DA: The Molecular Pathogenesis of Clostridium difficile -associated Disease. Curr Infect Dis Rep. 2008, 10 (2): 111-115. 10.1007/s11908-008-0020-0.View ArticlePubMedGoogle Scholar
- Pothoulakis C: Effects of Clostridium difficile toxins on epithelial cell barrier. Ann N Y Acad Sci. 2000, 915: 347-356.View ArticlePubMedGoogle Scholar
- Brito GA, Fujji J, Carneiro-Filho BA, Lima AA, Obrig T, Guerrant RL: Mechanism of Clostridium difficile toxin A-induced apoptosis in T84 cells. J Infect Dis. 2002, 186 (10): 1438-1447. 10.1086/344729.View ArticlePubMedGoogle Scholar
- Hippenstiel S, Schmeck B, N'Guessan PD, Seybold J, Krull M, Preissner K, Eichel-Streiber CV, Suttorp N: Rho protein inactivation induced apoptosis of cultured human endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2002, 283 (4): L830-838.View ArticlePubMedGoogle Scholar
- Thelestam M, Chaves-Olarte E: Cytotoxic effects of the Clostridium difficile toxins. Curr Top Microbiol Immunol. 2000, 250: 85-96.PubMedGoogle Scholar
- Weiss K: Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int J Antimicrob Agents. 2009, 33 (1): 4-7. 10.1016/j.ijantimicag.2008.07.011.View ArticlePubMedGoogle Scholar
- Kurtz CB, Cannon EP, Brezzani A, Pitruzzello M, Dinardo C, Rinard E, Acheson DW, Fitzpatrick R, Kelly P, Shackett K, et al: GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother. 2001, 45 (8): 2340-2347. 10.1128/AAC.45.8.2340-2347.2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Castagliuolo I, Karalis K, Valenick L, Pasha A, Nikulasson S, Wlk M, Pothoulakis C: Endogenous corticosteroids modulate Clostridium difficile toxin A-induced enteritis in rats. Am J Physiol Gastrointest Liver Physiol. 2001, 280 (4): G539-545.PubMedGoogle Scholar
- Kelly CP, Becker S, Linevsky JK, Joshi MA, O'Keane JC, Dickey BF, LaMont JT, Pothoulakis C: Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J Clin Invest. 1994, 93 (3): 1257-1265. 10.1172/JCI117080.PubMed CentralView ArticlePubMedGoogle Scholar
- Kyne L, Hamel MB, Polavaram R, Kelly CP: Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002, 34 (3): 346-353. 10.1086/338260.View ArticlePubMedGoogle Scholar
- McDonald LC, Owings M, Jernigan DB: Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis. 2006, 12 (3): 409-415.PubMed CentralView ArticlePubMedGoogle Scholar
- Naaber P, Mikelsaar RH, Salminen S, Mikelsaar M: Bacterial translocation, intestinal microflora and morphological changes of intestinal mucosa in experimental models of Clostridium difficile infection. J Med Microbiol. 1998, 47 (7): 591-598.View ArticlePubMedGoogle Scholar
- Bartlett JG: New Antimicrobial Agents for Patients With Clostridium difficile Infections. Curr Infect Dis Rep. 2009, 11 (1): 21-28. 10.1007/s11908-009-0004-8.View ArticlePubMedGoogle Scholar
- McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z, et al: A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994, 271 (24): 1913-1918. 10.1001/jama.271.24.1913.View ArticlePubMedGoogle Scholar
- Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmarker S, Bowen K, Borjal D, et al: The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000, 31 (4): 1012-1017. 10.1086/318130.View ArticlePubMedGoogle Scholar
- Klarin B, Wullt M, Palmquist I, Molin G, Larsson A, Jeppsson B: Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics. Acta Anaesthesiol Scand. 2008, 52 (8): 1096-1102.View ArticlePubMedGoogle Scholar
- Wullt M, Hagslatt ML, Odenholt I: Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis. 2003, 35 (6–7): 365-367. 10.1080/00365540310010985.View ArticlePubMedGoogle Scholar
- Lawrence SJ, Korzenik JR, Mundy LM: Probiotics for recurrent Clostridium difficile disease. J Med Microbiol. 2005, 54 (Pt 9): 905-906. 10.1099/jmm.0.46096-0.View ArticlePubMedGoogle Scholar
- Pochapin M: The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol. 2000, 95 (1 Suppl): S11-13. 10.1016/S0002-9270(99)00809-6.View ArticlePubMedGoogle Scholar
- Plummer S, Weaver MA, Harris JC, Dee P, Hunter J: Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol. 2004, 7 (1): 59-62.PubMedGoogle Scholar
- McFarland LV: Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006, 101 (4): 812-822. 10.1111/j.1572-0241.2006.00465.x.View ArticlePubMedGoogle Scholar
- Bojrab GG: Novel lactobacillus bulgaricus strain and compositions. United States Patent Application. 2006Google Scholar
- Bojrab GG: Novel lactobacillus bulgaricus strain and compositions. United States Patent Application. 2006Google Scholar
- Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A, Zucco F: The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol. 2005, 21 (1): 1-26. 10.1007/s10565-005-0085-6.View ArticlePubMedGoogle Scholar
- Banerjee P, Lenz D, Robinson JP, Rickus JL, Bhunia AK: A novel and simple cell-based detection system with a collagen-encapsulated B-lymphocyte cell line as a biosensor for rapid detection of pathogens and toxins. Lab Invest. 2008, 88 (2): 196-206. 10.1038/labinvest.3700703.View ArticlePubMedGoogle Scholar
- Gueimonde M, Jalonen L, He F, Hiramatsu M, Salminen S: Adhesion and competitive inhibition and displacement of human enteropathogens by selected lactobacilli. Food Res Int. 2006, 39 (4): 467-471. 10.1016/j.foodres.2005.10.003.View ArticleGoogle Scholar
- Morita H, He F, Fuse T, Ouwehand AC, Hashimoto H, Hosoda M, Mizumachi K, Kurisaki J: Adhesion of lactic acid bacteria to caco-2 cells and their effect on cytokine secretion. Microbiol Immunol. 2002, 46 (4): 293-297.View ArticlePubMedGoogle Scholar
- Wampler JL, Kim KP, Jaradat Z, Bhunia AK: Heat shock protein 60 acts as a receptor for the Listeria adhesion protein in Caco-2 cells. Infect Immun. 2004, 72 (2): 931-936. 10.1128/IAI.72.2.931-936.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C: Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun. 1996, 64 (12): 5225-5232.PubMed CentralPubMedGoogle Scholar
- Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C: Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. 1999, 67 (1): 302-307.PubMed CentralPubMedGoogle Scholar
- Ingrassia I, Leplingard A, Darfeuille-Michaud A: Lactobacillus casei DN-114001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's disease patients to adhere to and to invade intestinal epithelial cells. Appl Environ Microbiol. 2005, 71 (6): 2880-2887. 10.1128/AEM.71.6.2880-2887.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Lee YK, Puong KY, Ouwehand AC, Salminen S: Displacement of bacterial pathogens from mucus and Caco-2 cell surface by lactobacilli. J Med Microbiol. 2003, 52 (Pt 10): 925-930. 10.1099/jmm.0.05009-0.View ArticlePubMedGoogle Scholar
- Sun J, Le GW, Shi YH, Su GW: Factors involved in binding of Lactobacillus plantarum Lp6 to rat small intestinal mucus. Lett Appl Microbiol. 2007, 44 (1): 79-85. 10.1111/j.1472-765X.2006.02031.x.View ArticlePubMedGoogle Scholar
- Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CG: Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA. 2007, 104 (18): 7617-7621. 10.1073/pnas.0700440104.PubMed CentralView ArticlePubMedGoogle Scholar
- Hudault S, Lievin V, Bernet-Camard MF, Servin AL: Antagonistic activity exerted in vitro and in vivo by Lactobacillus casei (strain GG) against Salmonella typhimurium C5 infection. Appl Environ Microbiol. 1997, 63 (2): 513-518.PubMed CentralPubMedGoogle Scholar
- Johnson-Henry KC, Donato KA, Shen-Tu G, Gordanpour M, Sherman PM: Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function. Infect Immun. 2008, 76 (4): 1340-1348. 10.1128/IAI.00778-07.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.